All Oncology News

Trastuzumab rezetecan reduced the risk of disease progression or death by 78% vs pyrotinib plus capecitabine in pretreatedHER2+ advanced breast cancer,

Taylor Brooks, MD, discusses ways that the availability of CAR T-cell therapies has augmented the relapsed/refractory LBCL treatment paradigm.

Switching to camizestrant plus a CDK4/6 inhibitor delayed symptom deterioration and improved QOL in HR+ breast cancer with the emergence of ESR1 mutations.

Atezolizumab plus bevacizumab displayed preliminary signs of a TTFS benefit vs TACE in intermediate-stage HCC.

A study suggests that breast cancer patients with obesity could benefit from lipid lowering therapies and should avoid high-fat weight loss regimens.

A data safety monitoring board recommended the continuation of a study of Bria-IMT plus immune checkpoint inhibition in metastatic breast cancer.

Arlo-cel achieved a high ORR and CR rate with durable responses and favorable safety in relapsed/refractory multiple myeloma.

The FDA granted fast track to EO2463, an OncoMimics immunotherapy, for low–tumor burden follicular lymphoma in the watch-and-wait setting.

Atezolizumab plus BCG did not extend EFS vs BCG alone in BCG-naive, high-risk non–muscle invasive bladder cancer.

XS003 shows bioequivalence to nilotinib at half the dose with a reduced food effect for patients with CML.

CAR2219 induced high response rates in relapsed/refractory LBCL, and the role of post-infusion maintenance therapy is worthy of further study.

Taylor Brooks, MD, discusses data that supported the FDA approvals of liso-cel across LBCL treatment settings and details of the agent’s toxicity profile.

The FDA granted orphan drug designation to HLX43 for thymic epithelial tumors

Final DeFi trial results show sustained responses, improved PROs, and a stable safety profile with long-term nirogacestat in desmoid tumors.

Buparlisib plus paclitaxel did not show an improvement in OS vs paclitaxel alone in PD-1/PD-L1–pretreated recurrent/metastatic HNSCC.

The FDA granted fast track to NBM-BMX, a HDAC8 inhibitor, for metastatic uveal melanoma.

Aaron Gerds, MD, MS, discusses the role of BTK inhibitors in CLL, real-world data with CAR T-cell therapies in LBCL, and JAK inhibitors for myelofibrosis.

A reduced docetaxel regimen helped lower rates of AEs when combined with daolutamide and ADT in mHSPC.

EIK1001 plus pembrolizumab and chemo showed a 64% ORR and manageable safety in first-line stage IV NSCLC, per phase 2 TeLuRide-005 data.

Zabilugene almadenorepvec plus SOC therapy was active in patients with treatment-naive metasatic PDAC.

Zanzalintinib plus atezolizumab demonstrate potential chemotherapy-free option in previously treated metastatic CRC.

Neoadjuvant nivolumab plus ipilimumab proved superior to adjuvant nivolumab alone with longer follow-up data from the NADINA trial in stage III melanoma.

Adjuvant atezolizumab improved DFS and OS in patients with muscle-invasive bladder cancer who tested positive for ctDNA after radical cystectomy.

Nivolumab plus ipilimumab improved PFS and response rates vs nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns.

Camrelizumab plus famitinib led to superior PFS and OS outcomes vs chemotherapy in frontline recurrent/metastatic cervical cancer.

Bemarituzumab/mFOLFOX6 produced an OS advantage over placebo/mFOLFOX6 in FGFR2b-overexpressing gastric/GEJ cancer; this was attenuated at longer follow-up.

Long-term data from the ALINA trail continued to support the use of adjuvant alectinib in resected, ALK-positive, early stage non–small cell lung cancer.

IO102-IO103 plus pembrolizumab was associated with a clinically relevant improvement in median progression-free survival.